Hamilton James C

CMO Hamilton James sells 10,000 ARWR shares at $64.19; stock now at $60.67, down 6.0% in 30 days

Hamilton James C, Chief Medical Officer, sold 10,000 shares of ARROWHEAD PHARMACEUTICALS at $64.19 on 2026-03-05, reducing his holdings by 4.0% to 236,958 shares. The stock has declined 6.0% over the subsequent 30 days and currently trades at $60.67, down 16.9% from its 52-week high. His cross-ticker track record shows 15 prior sells with a 90-day well-timed rate of 87.50%, indicating his sales have historically preceded stock declines, though his same-ticker history at ARWR contains five prior sales from January 2026 with mixed 30-day returns (ranging 0.1% to 11.1%) and no measurable 90-day outcomes yet. The company reported strong recent fundamentals—$264.0M quarterly revenue, $30.8M net income, and +23258.2% annual revenue growth—but the elevated P/E of 42.13 and the stock's 11.9% decline over 90 days suggest valuation or sentiment headwinds despite operational strength.

CMO Hamilton James C sells 40,164 shares for $2.5M across 7 tranches; stock +74.8% in 90 days, well above insider's cross-ticker baseline.

Hamilton James C, Chief Medical Officer, executed 7 separate sales totaling 40,164 shares for $2,534,661.46 on 2026-01-05, reducing holdings by 18.9%. The sales occurred at prices ranging from $61.24 to $68.00, with a blended average of $63.11, while the stock now trades at $63.88. At Arrowhead, his prior 5 tracked sales were well-timed 80% of the time at the 90-day mark; however, this institution remains unprofitable (net income: $-175,241,000.00 in the latest full fiscal year) despite sharp revenue growth of 23258.2%. The broader context is material: the stock has risen 74.8% over 90 days and sits only 9.8% below its 52-week high, while his cross-ticker track record shows an 87.50% well-timed rate on prior sells but a negative 90-day return average of -8.4%, indicating recent sell timing has diverged from his historical pattern. The scale of this single-day, multi-tranche liquidation—18.9% of holdings—merits examination in relation to ongoing research or commercial developments at the company.

CMO Hamilton James C sold 20,000 shares of ARWR at $35.00 (700K); stock now at $36.12 after +29.9% 30d surge.

Hamilton James C, Chief Medical Officer, sold 20,000 shares at $35.00 on 2025-10-01, reducing his stake from 232.1K to 212.1K shares. The sale occurred within a 30-day surge of +29.9% and 90-day surge of +115.1%, with the stock currently trading at $36.12 near its 52-week high. Notably, his prior trades at ARWR show a 5 of 5 well-timed pattern at the 90-day mark, with negative post-sale returns (ranging -1.7% to -10.4%) across the same ticker, though the cross-ticker track record (7 prior sells) averaged -22.7% 90-day return with 100% well-timed rate. Against this backdrop, the company faces severe headwinds: revenue contracted -98.5% year-over-year to $27.8M in the latest quarter, net income was negative $-175.2M, and the company remained unprofitable over the full fiscal year. The insider's sale near the stock's 52-week high, coupled with the company's dramatic revenue collapse and persistent losses, warrants investor attention.